The European Commission approved a contract with BioNTech and Pfizer involving the initial purchase of 200 million doses of the duo’s BNT162b2 plus an option to purchase an additional 100 million doses upon evidence of the investigational product’s safety and efficacy. Member nations in Europe can donate the vaccine to lower and middle-income countries or redirect to other European sovereigns. The move adds to the growing European COVID-19 vaccine portfolio including deals signed with AstraZeneca, Sanofi-GSK and Janssen Pharmacuetica NV. Europe has recently concluded successful exploratory discussions with Germany’s CureVac and Moderna. Europe’s goal is to ensure adequate readiness and preparation for vaccination once these investigational products are deemed safe and effective.
For more on this topic, visit the source at the European Commission website.